These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21355922)

  • 1. Putting the call out for more research: the poor evidence base for treating methamphetamine withdrawal.
    Pennay AE; Lee NK
    Drug Alcohol Rev; 2011 Mar; 30(2):216-22. PubMed ID: 21355922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barriers to methamphetamine withdrawal treatment in Australia: findings from a survey of AOD service providers.
    Pennay AE; Lee NK
    Drug Alcohol Rev; 2009 Nov; 28(6):636-40. PubMed ID: 19930017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effects and management of methamphetamine abuse.
    Romanelli F; Smith KM
    Pharmacotherapy; 2006 Aug; 26(8):1148-56. PubMed ID: 16863490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility and acceptability of approach bias modification during methamphetamine withdrawal and related methamphetamine use outcomes.
    Manning V; Garfield JBB; Mroz K; Campbell SC; Piercy H; Staiger PK; Lum JAG; Lubman DI; Verdejo-Garcia A
    J Subst Abuse Treat; 2019 Nov; 106():12-18. PubMed ID: 31540606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Review of Methamphetamine Dependence and Withdrawal Treatment: A Focus on Anxiety Outcomes.
    Hellem TL
    J Subst Abuse Treat; 2016 Dec; 71():16-22. PubMed ID: 27776672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Withdrawal Symptoms in Men Addicted to Methamphetamine With Transcranial Magnetic Stimulation: A Randomized Clinical Trial.
    Liang Y; Wang L; Yuan TF
    JAMA Psychiatry; 2018 Nov; 75(11):1199-1201. PubMed ID: 30208372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal.
    Cruickshank CC; Montebello ME; Dyer KR; Quigley A; Blaszczyk J; Tomkins S; Shand D
    Drug Alcohol Rev; 2008 May; 27(3):326-33. PubMed ID: 18368615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot randomised controlled trial of modafinil during acute methamphetamine withdrawal: feasibility, tolerability and clinical outcomes.
    Lee N; Pennay A; Hester R; McKetin R; Nielsen S; Ferris J
    Drug Alcohol Rev; 2013 Jan; 32(1):88-95. PubMed ID: 22630616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing the effect of buprenorphine and methadone in the reduction of methamphetamine craving: a randomized clinical trial.
    Ahmadi J; Razeghian Jahromi L
    Trials; 2017 Jun; 18(1):259. PubMed ID: 28587620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The nature, time course and severity of methamphetamine withdrawal.
    McGregor C; Srisurapanont M; Jittiwutikarn J; Laobhripatr S; Wongtan T; White JM
    Addiction; 2005 Sep; 100(9):1320-9. PubMed ID: 16128721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of environmental enrichment during induction of methamphetamine dependence on the behavioral withdrawal symptoms in rats.
    Hajheidari S; Miladi-Gorji H; Bigdeli I
    Neurosci Lett; 2015 Sep; 605():39-43. PubMed ID: 26275348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased self-reported impulsivity in methamphetamine users maintaining drug abstinence.
    Jones HW; Dean AC; Price KA; London ED
    Am J Drug Alcohol Abuse; 2016 Sep; 42(5):500-506. PubMed ID: 27398730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and correlates of depressive symptoms during early methamphetamine withdrawal in Han Chinese population.
    Zhang J; Xie Y; Su H; Tao J; Sun Y; Li L; Liang H; He R; Han B; Lu Y; Sun H; Wei Y; Guo J; Zhang XY; He J
    Drug Alcohol Depend; 2014 Sep; 142():191-6. PubMed ID: 25001276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methamphetamine withdrawal and the restoration of cognitive functions - a study over a course of 6 months abstinence.
    Proebstl L; Krause D; Kamp F; Hager L; Manz K; Schacht-Jablonowsky M; Straif M; Riebschläger M; Neumann S; Schreiber A; Soyka M; Koller G
    Psychiatry Res; 2019 Nov; 281():112599. PubMed ID: 31629302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing methamphetamine withdrawal in recently abstinent methamphetamine users: a pilot field study.
    Mancino MJ; Gentry BW; Feldman Z; Mendelson J; Oliveto A
    Am J Drug Alcohol Abuse; 2011 Mar; 37(2):131-6. PubMed ID: 21219261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methamphetamine abstinence induces changes in μ-opioid receptor, oxytocin and CRF systems: Association with an anxiogenic phenotype.
    Georgiou P; Zanos P; Garcia-Carmona JA; Hourani S; Kitchen I; Laorden ML; Bailey A
    Neuropharmacology; 2016 Jun; 105():520-532. PubMed ID: 26896754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychiatric comorbidity of methamphetamine dependence in a forensic sample.
    Kalechstein AD; Newton TF; Longshore D; Anglin MD; van Gorp WG; Gawin FH
    J Neuropsychiatry Clin Neurosci; 2000; 12(4):480-4. PubMed ID: 11083165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. METHAMPHETAMINE: WHERE WILL THE STAMPEDE TAKE US?
    Sullivan D; McDonough Michael
    J Law Med; 2015 Sep; 23(1):41-9. PubMed ID: 26554196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical management of psychostimulant withdrawal: review of the evidence.
    Li MJ; Shoptaw SJ
    Addiction; 2023 Apr; 118(4):750-762. PubMed ID: 36401591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The beta-lactam antibiotic ceftriaxone inhibits physical dependence and abstinence-induced withdrawal from cocaine, amphetamine, methamphetamine, and clorazepate in planarians.
    Rawls SM; Cavallo F; Capasso A; Ding Z; Raffa RB
    Eur J Pharmacol; 2008 Apr; 584(2-3):278-84. PubMed ID: 18342307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.